These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23083349)

  • 1. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
    Ghosh N; Chaki R; Mandal SC
    Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.
    Fiorino G; Correale C; Fries W; Repici A; Malesci A; Danese S
    Expert Rev Clin Immunol; 2010 Jul; 6(4):567-72. PubMed ID: 20594130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-adhesion molecules: is gut specificity the key for a good safety profile?
    Allen PB
    Curr Drug Deliv; 2012 Jul; 9(4):333-7. PubMed ID: 22762276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
    Sugiura T; Kageyama S; Andou A; Miyazawa T; Ejima C; Nakayama A; Dohi T; Eda H
    J Crohns Colitis; 2013 Dec; 7(11):e533-42. PubMed ID: 23623333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ; Munday JR
    Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.
    Stefanelli T; Malesci A; De La Rue SA; Danese S
    Autoimmun Rev; 2008 May; 7(5):364-9. PubMed ID: 18486923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha 4 integrin blockade in inflammatory bowel disease.
    Ghosh S
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii70-2. PubMed ID: 14532154
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
    Sandborn WJ; Yednock TA
    Am J Gastroenterol; 2003 Nov; 98(11):2372-82. PubMed ID: 14638336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
    Ghosh S
    Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: anti-adhesion therapies for inflammatory bowel disease.
    Lobatón T; Vermeire S; Van Assche G; Rutgeerts P
    Aliment Pharmacol Ther; 2014 Mar; 39(6):579-94. PubMed ID: 24479980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.